Skip Navigation


JAC Advance Access originally published online on February 4, 2008
Journal of Antimicrobial Chemotherapy 2008 61(4):786-791; doi:10.1093/jac/dkm545
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
61/4/786    most recent
dkm545v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Margerison, E. S.
Right arrow Articles by Elston, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Margerison, E. S.
Right arrow Articles by Elston, R. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

The HIV-1 protease substitution K55R: a protease-inhibitor-associated substitution involved in restoring viral replication

E. S. Margerison1,*, M. Maguire1, D. Pillay2, P. Cane2 and R. C. Elston1,{dagger}

1 GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK 2 Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK

Received 17 September 2007; returned 4 November 2007; revised 17 December 2007; accepted 18 December 2007

* Correspondence address. Lab21 Ltd, 184 Cambridge Science Park, Milton Road, Cambridge CB4 0GA, UK. Tel: +44-1223-395484; Fax: +44-1223-395491; E-mail: liz.margerison{at}lab-21.com

Objectives: The identification and in vitro characterization of novel protease mutations strongly associated with known protease resistance mutations.

Methods: The association between pairs of protease amino acid substitutions was identified using a database of protease sequences derived from protease inhibitor-experienced patients (n = 803). In vitro characterization included drug susceptibility and viral replication studies performed on recombinant viruses harbouring site-directed mutations.

Results: The K55R mutation, which is not a natural polymorphism, was identified to be strongly associated with protease mutations M46I/L and to a lesser extent L24I, I54V and V82A/T/S/F. In vitro characterization of the K55R substitution indicated a primary role for this substitution in increasing replicative capacity in the presence of specific protease mutations.

Conclusions: The K55R mutation is a secondary drug resistance mutation that can improve viral replication capacity in the presence of other primary protease mutations.

Keywords: HIV , fitness , resistance , mutations

{dagger} Present address. Roche Products Limited, Hexagon Place, Shire Park, Welwyn Garden City AL7 1TW, UK.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.